Citation Impact
Citing Papers
Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies
2008 Standout
Expanded therapeutic potential in activity space of next-generation 5-nitroimidazole antimicrobials with broad structural diversity
2013 StandoutNobel
Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women
2010 StandoutScience
High Coverage of ART Associated with Decline in Risk of HIV Acquisition in Rural KwaZulu-Natal, South Africa
2013 StandoutScience
The Evolution and Future of Earth’s Nitrogen Cycle
2010 StandoutScience
CD4+ Count–Guided Interruption of Antiretroviral Treatment
2006 Standout
Characterization of a canine homolog of hepatitis C virus
2011 StandoutNobel
A drug-controllable tag for visualizing newly synthesized proteins in cells and whole animals
2008 StandoutNobel
Incidence of Myocardial Infarction in Randomized Clinical Trials of Protease Inhibitor-Based Antiretroviral Therapy: An Analysis of Four Different Protease Inhibitors
2003
Adherence to HAART Regimens
2003
Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis
2020
Bioorthogonal Chemistry: Fishing for Selectivity in a Sea of Functionality
2009 StandoutNobel
Apoptosis in the nervous system
2000 StandoutNature
Limitations of non-invasive tests for assessment of liver fibrosis
2020
Antibiotic resistance in bacteria from shrimp farming in mangrove areas
2005
Toxicity evaluation with Vibrio fischeri test of organic chemicals used in aquaculture
2007
NAFLD: Reporting Histologic Findings in Clinical Practice
2020
Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells
2004
A global perspective on the use, sales, exposure pathways, occurrence, fate and effects of veterinary antibiotics (VAs) in the environment
2006 Standout
Treatment of Pulmonary Arterial Hypertension
2004 Standout
qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis
2019
Decreased HIV Transmission after a Policy of Providing Free Access to Highly Active Antiretroviral Therapy in Taiwan
2004
Natural history of HIV infection in the_era of combination antiretroviral therapy
1999
Unpacking factors influencing antimicrobial use in global aquaculture and their implication for management: a review from a systems perspective
2017
Antibiotics in the aquatic environment – A review – Part I
2009 Standout
Copper‐Catalyzed Synthesis of N‐Sulfonyl‐1,2,3‐triazoles: Controlling Selectivity
2007 StandoutNobel
A Lateral Flow Assay for Quantitative Detection of Amplified HIV-1 RNA
2012
Long-Term HIV/AIDS Survival Estimation in the Highly Active Antiretroviral Therapy Era
2003
HLA-B*5701 Screening for Hypersensitivity to Abacavir
2008 Standout
Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients
2010
Structural Basis for the Resilience of Efavirenz (DMP-266) to Drug Resistance Mutations in HIV-1 Reverse Transcriptase
2000
Mechanisms of NAFLD development and therapeutic strategies
2018 Standout
Biology of Natural Killer Cells
1989 Standout
Treatment for Adult HIV Infection
2006
Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials
2020
The growing impact of click chemistry on drug discovery
2003 StandoutNobel
Non-alcoholic fatty liver disease
2021 Standout
Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance 1 1Edited by J. Karn
1998
Cardiovascular and Cerebrovascular Events in Patients Treated for Human Immunodeficiency Virus Infection
2003
Chemical remodelling of cell surfaces in living animals
2004 StandoutNatureNobel
Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors 1 1Edited by J. Karn
2001
Prophylaxis against Opportunistic Infections in Patients with Human Immunodeficiency Virus Infection
2000
Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date
2019
The Natural History of Nitrogen Fixation
2004
Structured Treatment Interruptions for the Management of HIV Infection
2001
HIV Drug Resistance
2004
The challenge of emerging and re-emerging infectious diseases
2004 StandoutNature
Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease
2019
Phenylethylthiazolylthiourea (PETT) Non-nucleoside Inhibitors of HIV-1 and HIV-2 Reverse Transcriptases
2000
Copper(I)‐Catalyzed Cycloaddition of Organic Azides and 1‐Iodoalkynes
2009 StandoutNobel
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
2005 Standout
The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance
2001
Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study
2005
BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain
2005 StandoutNature
The CD4 lymphocyte count and risk of clinical progression
2006
Past, present and future perspectives in nonalcoholic fatty liver disease
2019
A 20-year retrospective review of global aquaculture
2021 StandoutNature
Serious Fatal and Nonfatal Non-AIDS-Defining Illnesses in Europe
2010
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies
2002
Veterinary Medicines in the Environment
2004
Causes of death among HIV‐infected patients in the era of highly active antiretroviral therapy, Bordeaux, France, 1998–1999
2002
Steady‐State Pharmacokinetics of Emtricitabine and Tenofovir Disoproxil Fumarate Administered Alone and in Combination in Healthy Volunteers
2007
Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study
2015 Standout
Evaluation of antiretrovirals in animal models of HIV infection
2009
Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection
2016 StandoutNatureNobel
Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034
2006
Stem cell-derived polarized hepatocytes
2020 StandoutNobel
Abacavir-Lamivudine-Zidovudine vs Indinavir-Lamivudine-Zidovudine in Antiretroviral-Naive HIV-Infected Adults<SUBTITLE>A Randomized Equivalence Trial</SUBTITLE>
2001
Guidelines for Using Antiretroviral Agents among HIV-Infected Adults and Adolescents: The Panel on Clinical Practices for Treatment of HIV*
2002
Binding of the Second Generation Non-nucleoside Inhibitor S-1153 to HIV-1 Reverse Transcriptase Involves Extensive Main Chain Hydrogen Bonding
2000
Efavirenz
2001
Adherence to Medication
2005 Standout
Prognostic Factors for Survival in Human Immunodeficiency Virus–associated Pulmonary Arterial Hypertension
2003
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
2023 Standout
Copper(I)-Catalyzed Synthesis of Azoles. DFT Study Predicts Unprecedented Reactivity and Intermediates
2004 StandoutNobel
Fluorine in medicinal chemistry
2007 Standout
SuFEx Click Chemistry Enabled Late-Stage Drug Functionalization
2018 StandoutNobel
Cu and Cu-Based Nanoparticles: Synthesis and Applications in Catalysis
2016 Standout
Steric and Dynamic Parameters Influencing In Situ Cycloadditions to Form Triazole Inhibitors with Crystalline Acetylcholinesterase
2016 StandoutNobel
Combination Antiretroviral Therapy and the Risk of Myocardial Infarction
2003 Standout
Induction of Tumor Immunity by Removing CD25+CD4+ T Cells: A Common Basis Between Tumor Immunity and Autoimmunity
1999 StandoutNobel
Use of chemicals and biological products in Asian aquaculture and their potential environmental risks: a critical review
2012
Global trends in antimicrobial use in food animals
2015 Standout
Multidimensional SuFEx Click Chemistry: Sequential Sulfur(VI) Fluoride Exchange Connections of Diverse Modules Launched From An SOF4 Hub
2017 StandoutNobel
Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004
2008
Determination and fate of oxytetracycline and related compounds in oxytetracycline production wastewater and the receiving river
2007
Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial
2019
HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis
2006
Antimicrobial use in aquaculture re‐examined: its relevance to antimicrobial resistance and to animal and human health
2013
Human Dendritic Cells Activate Resting Natural Killer (NK) Cells and Are Recognized via the NKp30 Receptor by Activated NK Cells
2002 StandoutNobel
Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy
2007
Antiretroviral Treatment of Adult HIV Infection
2014
MICROGLIA AS MEDIATORS OF INFLAMMATORY AND DEGENERATIVE DISEASES
1999
A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1
2000
The Changing Incidence of AIDS Events in Patients Receiving Highly Active Antiretroviral Therapy
2005
Biogeochemical Controls and Feedbacks on Ocean Primary Production
1998 StandoutScience
Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study
2003
Clinical Outcome of Patients with HIV-1 Infection according to Immunologic and Virologic Response after 6 Months of Highly Active Antiretroviral Therapy
2000
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection
2015 Standout
Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries
2006
Structure of HIV-1 reverse transcriptase bound to an inhibitor active against mutant reverse transcriptases resistant to other nonnucleoside inhibitors
2004 StandoutNobel
Trichodesmium , a Globally Significant Marine Cyanobacterium
1997 Science
Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies
2003
Latent reservoirs of HIV: Obstacles to the eradication of virus
1999
Ruthenium-Catalyzed Cycloaddition of Alkynes and Organic Azides
2005 StandoutNobel
Cu-Catalyzed Azide−Alkyne Cycloaddition
2008 StandoutNobel
Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count
2007
Second-Generation Difluorinated Cyclooctynes for Copper-Free Click Chemistry
2008 StandoutNobel
Uptake of Veterinary Medicines from Soils into Plants
2006
Fast detection of liver fibrosis with collagen-binding single-nanometer iron oxide nanoparticles via T 1 -weighted MRI
2023 StandoutNobel
Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus
2016 StandoutNobel
Design of MKC-442 (Emivirine) Analogues with Improved Activity Against Drug-Resistant HIV Mutants
1999
Works of Veronica Miller being referenced
Hepatitis C virus drug resistance–associated substitutions: State of the art summary
2015
Changing patterns of mortality across Europe in patients infected with HIV-1
1998
Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients
1996
ANTIVIRAL ACTIVITY OF TENOFOVIR (PMPA) AGAINST NUCLEOSIDE-RESISTANT CLINICAL HIV SAMPLES
2001
HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy
2000
World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing
2001
Resistance to Protease Inhibitors
2001
The virological response to highly active antiretroviral therapy over the first 24 weeks of therapy according to the pre-therapy viral load and the weeks 4–8 viral load
2001
Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA
2000
Early viral brain invasion in iatrogenic human immunodeficiency virus infection
1992
Structured treatment interruptions in antiretroviral management of HIV-1
2001
HIV-1 Viral Load Assays for Resource-Limited Settings
2006
NAFLD — sounding the alarm on a silent epidemic
2020
HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance
2006
Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure
2000
Pharmacovigilance and global HIV/AIDS
2012
The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load
2000
Association of Virus Load, CD4 Cell Count, and Treatment with Clinical Progression in Human Immunodeficiency Virus–Infected Patients with Very Low CD4 Cell Counts
2002
Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples
2000
Regulatory Science and Drug Approval for Alcoholic and Nonalcoholic Steatohepatitis
2016
CD4 Lymphocyte Count as a Predictor of the Duration of Highly Active Antiretroviral Therapy–Induced Suppression of Human ImmunodeficiencyVirus Load
1999
Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy
1999
Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum
2019
A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs
1998
Antibacterial residues in marine sediments and invertebrates following chemotherapy in aquaculture
1996
Mutational Patterns in the HIV Genome and Cross-Resistance following Nucleoside and Nucleotide Analogue Drug Exposure
2001
Relations among CD4 Lymphocyte Count Nadir, Antiretroviral Therapy, and HIV-1 Disease Progression: Results from the EuroSIDA Study
1999
A Family of Insertion Mutations between Codons 67 and 70 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confer Multinucleoside Analog Resistance
1999
A phenyl-beta-galactoside-specific monoclonal antibody reactive with murine and rat NK cells.
1986
Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science
2017
Modification of the Fe Protein of Nitrogenase in Natural Populations of Trichodesmium thiebautii
1993
Resistance to Protease Inhibitors
2001
Patterns of Resistance and Cross-Resistance to Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitors in Patients Treated with the Nonnucleoside Reverse Transcriptase Inhibitor Loviride
1998